Identification of p185(neu) sequences required for monoclonal antibody- or ligand-mediated receptor signal attenuation

DNA and Cell Biology

Volumn 16, Issue 12, 1997, Pages 1395-1405

  Qian, Xiaolan ^a,c   O'Rourke, Donald M ^a   Drebin, Jeffrey ^b   Zhao, Huizhen ^a   Wang, Qiang ^a   Greene, Mark I ^a,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; ONCOPROTEIN; ONCOPROTEIN NEU P 185; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR 2; RECOMBINANT PROTEIN;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CARCINOGENICITY; CELL TRANSFORMATION; CONTROLLED STUDY; DELETION MUTANT; ENDOCYTOSIS; FIBROBLAST; FLOW CYTOMETRY; MOUSE; NONHUMAN; NUDE MOUSE; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN DEGRADATION; RECEPTOR DOWN REGULATION; ANIMAL; BINDING SITE; COMPARATIVE STUDY; DOWN REGULATION; DRUG EFFECT; DRUG SCREENING; GENETICS; IMMUNOLOGY; METABOLISM; MUTATION; PHOSPHORYLATION;

ANIMALS; ANTIBODIES, MONOCLONAL; BINDING SITES; DOWN-REGULATION; ENDOCYTOSIS; EPIDERMAL GROWTH FACTOR; MICE; MICE, NUDE; MUTATION; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECOMBINANT PROTEINS; TUMOR STEM CELL ASSAY;

EID: 0031283001     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.1997.16.1395     Document Type: Article

References (19)

1. ARTALEJO, C.R., LEMMON, M.A., SCHLESSINGER, J., and PALFREY, H.C. (1997). Specific for the PH domain of dynamin-1 in the regulation of rapid endocytosis in adrenal chromaffin cells. EMBO J. 16, 1565-1574.
2. BARGMANN, C.I., HUNG, M.-C., and WEINBERG, R.A. (1988). Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion. EMBO J. 7, 2043-2052.
3. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14, 737-744.
4. BATZER, A.G., ROTIN, D., URENA, J.M., SKOLINIK, E.Y., and SCHLESSINGER, J. (1994). Hierarchy of binding sites for Grb2 and She on the epidermal growth factor receptor. Mol. Cell. Biol. 14, 5192-5201.
5. BROWN, V.I., SHAH, N., SMITH, R., HELLMAN, M., JARETT, L., MIKAMI, Y., COHEN, E., QIAN, X., and GREENE, M.I. (1994). Demonstration by two-color flow cytometry that tyrosine kinase activity is required for down-modulation of the oncogenic neu receptor. DNA Cell Biol. 13, 193-209.
6. ras through the formation of c complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor. 73, 611-620.
7. CARTER, P., PRESTA, L., GORMAN, C.M., RIDGWAY, J.B.B., HENNER, D., WONG, W.L.T., ROWLAND, A.M., KOTTS, C., CARVER, M.E., and SHEPARD, H.M. (1992). Humanization of an anti-p185Her2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA. 89, 4285.
8. CHEN, W.S., LAZAR, C.S., LUND, K.A., WELSH, J.B., CHANG, C.-P., WALTON, G.M., DER, C.J., WILEY, H.S., GILL, G.N., and ROSENFELD, M.G. (1989). Functional independence of the epidermal growth factor receptor from a domain required for ligand-induced internalization and calcium regulation. Cell 59, 33-43.
9. DAMKE, H., BABA, T., WARNOCK, D.E., and SCHMID, S.L. (1994). Induction of mutant dynamin specifically blocks endocytic coated vesicle formation. J. Cell. Biol. 127, 915-34.
10. DOUGALL, W.C., QIAN, X., MILLER, M.J., and GREENE, M.I. (1996). Association of signaling proteins with a nonmitogenic heterodimeric complex composed of epidermal growth factor receptor and kinase-inactive p185c-neu. DNA Cell Biol. 15, 31-40.
11. DREBIN, J.A., LINK, V.C., STERN, D.F., WEINBERG, R.A., and GREENE, M.I. (1985). Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41, 695-706.
12. DREBIN, J.A., LINK, V.C., WEINBERG, R.A., and GREENE, M.I. (1986). Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc. Natl. Acad. Sci. USA 83, 9129-9133.
13. GALCHEVA-GARGOVA, Z., THEROUX, S.J., and DAVIS, R.D. (1995). The epidermal growth factor receptor is covalently linked to ubiquitin. Oncogene 11, 2649-2655.
14. GALE, N.W., LOWENSTEIN, E.J., SCHLESSINGER, J., and BARSAGI, D. (1993). Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on Ras. Nature 363, 88-92.
15. GIBOA, L., BEN-LEVY, R., YARDEN, Y., and HENIS, Y. (1995). Roles for a cytoplasmaic tyrosine kinase activity in the intemalization of Neu receptor with coated pits. J. Biol. Chem. 270, 7061-7067.
16. HELIN, K., and BEGUINOT, L. (1991). Intemalization and down-regulation of the humane epidermal growth factor receptor are regulated by the carboxyl-terminal tyrosines. J. Biol. Chem. 266, 8363-8368.
17. HICKE, L., and RIEZMAN, H. (1996). Ubiquitination of a yeast plasma membrane receptor signals its ligand-stimulated endocytosis. Cell 84, 277-287.
18. HINSHAW, J.E., and SCHMID, S.L. (1995). Dynamin self-assembles into rings suggesting a mechanism for coated vesicle budding. Nature 374, 190-192.
19. HONEGGER, A.M., DULL, T.J., FELDER, S., VAN OBBERGHEN, E., BELLOT, F., SZAPARY, D., SCHMIDT, A., ULLRICH, A., and SCHLESSINGER, J. (1987). Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing. Cell 51, 199-209.